Team Science conducted the PEARL study, which seeks to evaluate the efficacy, immunogenicity and safety of a live and attenuated nasal vaccine against respiratory syncytial virus in infants, boys and girls aged 6 to 22 months.
Team Science conducted the PEARL study, which seeks to evaluate the efficacy, immunogenicity and safety of a live and attenuated nasal vaccine against respiratory syncytial virus in infants, boys and girls aged 6 to 22 months.